NewBiologix, a Lausanne, Switzerland-based technology company developing a proprietary platform focused on engineering cell lines used to manufacture gene and cell therapies, raised $50M in Series A funding.
The round was led by Recipharm with participation from its co-founders, Igor Fish and Nicolas Mermod.
The company intends to use the funds to begin beta testing of the cell line prototypes with key collaborators by 2024.
NewBiologix is developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines. It is currently focused on recombinant adeno-associated virus (rAAV) vectors, the preferred delivery vehicle for gene therapies. Specifically, the company’s technologies will be applied to human (HEK-293) and mammalian (CHO) cell lines. These cell lines will be engineered to be readily adaptable to meet the viral vector demands and requirements over a full range of therapeutic indications to help partners address rare, chronic, and currently incurable diseases.
NewBiologix anticipates making viral production cell lines commercially available by 2026.
FinSMEs
11/05/2023